Navigation Links
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Date:9/21/2007

- Phase III trials now underway to evaluate vandetanib as second-line NSCLC

treatment in combination with docetaxel -

WILMINGTON, Del., Sept. 20 /PRNewswire/ -- Results published today in the Journal of Clinical Oncology(1) show that the AstraZeneca investigational once-daily oral anti-cancer drug vandetanib (ZACTIMA), in combination with docetaxel, improved progression free survival (PFS) in patients with advanced Non-Small Cell Lung Cancer (NSCLC).

The Phase II trial - Study 6 - compared the combination of vandetanib 100mg or 300mg plus docetaxel to standard docetaxel alone. The trial demonstrated that adding vandetanib to standard docetaxel therapy prolonged median PFS to 18.7 weeks and 17 weeks respectively, compared to 12 weeks with docetaxel alone.(2)

"Given the poor prognosis in advanced non-small cell lung cancer, an increase in time to disease progression can be meaningful to patients," said Study 6 lead author John Heymach, Assistant Professor of Thoracic Head/Neck Medical Oncology at the University of Texas MD Anderson Cancer Centre . "The results of Study 6 provide encouraging support, and reinforce further investigation with ZACTIMA in combination with chemotherapy in Phase III trials."

Based on these data, AstraZeneca has initiated a Phase III trial, currently underway, to evaluate vandetanib and docetaxel in second-line treatment of non-small cell lung cancer. The ZODIAC (ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer), trial is a randomised, double- blind study evaluating vandetanib 100mg in combination with docetaxel vs. docetaxel alone, in patients with locally advanced or metastatic NSCLC after failure of first-line treatment.

The study is recruiting and aims to enroll approximately 1400 patients worldwide at over 250 centers throughout Europe, North America, South America and Asia Pacific. The primary end points of the study are to assess PFS. Response rates and overall Sur
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
6. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
7. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
8. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
9. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
10. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  A recent study ... Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, ... versus an "onlay" design implant for isolated patellofemoral ... in function and pain scores, none of the ... osteoarthritis (OA). However, 53% of the patients in ...
(Date:8/27/2015)... , Aug. 27, 2015 Biosimilars ... (BPC) applauds the U.S. Food and Drug Administration ... distinguishable name in its draft guidance issued today. ... biological products proposes distinguishable names, calling for biological ... an FDA-designated suffix. This proposal reflects the agency,s ...
(Date:8/27/2015)... -- According to a new market research report "Medical ... Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End ... the Medical Lifting Sling Market is poised to reach USD 706.0 ... CAGR of 11.4 % from 2015 to 2020. ... T ables and 65 F ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... 2011 Reportlinker.com announces that a new market ... Gastric Cancer - Global Drug Forecasts ... 2011 http://www.reportlinker.com/p0479813/Gastric-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-–-Volume-I-2011.html ... Treatment Analysis to 2020 – Volume I 2011 ...
... April 12, 2011 Reportlinker.com announces that a new ... Bladder Cancer - Global Drug Forecasts and ... http://www.reportlinker.com/p0479812/Bladder-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020---Volume-1-2011.html Bladder Cancer ... - Volume 1 2011 Summary ...
Cached Medicine Technology:Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 2Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 3Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 4Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 5Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 6Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 7Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 8Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 9Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 10Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 11Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 12Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 13Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 14Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 15Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 16Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 17Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 18Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 19Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 20Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 21Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 22Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 2Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 3Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 4Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 5Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 6Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 7Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 8Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 9Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 10Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 11Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 12Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 13Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 14Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 15
(Date:8/30/2015)... ... 30, 2015 , ... SonaCare Medical, LLC, the makers of ... cancer, has announced the roll-out of its newest technology – called Sonafuse ... Mexico. , The Sonablate® technology currently in use at the San Javier Marina ...
(Date:8/29/2015)... Falls Church, VA (PRWEB) , ... August 30, ... ... Practices, **FDAnews Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... it's much more than a simple digital handwritten signature. , Clinical ...
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... ... due to insufficient scrotal support and protection against dribbled urine and sweat. "In ... from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides ...
(Date:8/29/2015)... ... ... Brands like Toppik , Eau Thermale Avene and Bliss are now ... of $49.00 was required to qualify for free standard shipping,” said Jennifer Ramirez, the ... customers regardless of the item’s selling price.” , With competitive pricing in the e-commerce ...
(Date:8/29/2015)... Calgary, AB (PRWEB) , ... August 29, 2015 ... ... congestive heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are ... conditions such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... Medicine (BUSM) and Boston Medical Center (BMC) found ... should be considered an important component among Russian ... behavior in the HIV at-risk population. This study ... Russia has one of the fastest-growing acquired immune ...
... A new motorcycle seat,accessory provides peace of mind ... about cancer," says Canadian author and patent-granted,motorcycle seat ... deficiency or loss of libido may also be ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080711/NYF005 ), "Many motorcycles ...
... KONG, July 11 /Xinhua-PRNewswire/ -- Xinyu Hengdeli Holdings,Limited ... the,"Group"; HKEx: 3389), a leading enterprise engaged in ... in China, announced the,grand opening of Vacheron Constantin ... is the second Vacheron Constantin boutique of,Hong Kong ...
... ANN ARBOR, Mich., July 11 A new national,ranking ... Health Centers among the country,s finest, with a rank of,13th ... specialized,care., The new rankings, compiled by U.S. News & ... in a row that U-M has been named,to the honor ...
... HBO has acquired the pilot,"Fat Sells" co-created by ... Gren Wells. Academy Award winner Forest Whitaker ("The,Last King ... Broome on,this one-hour family drama set in the world ... Wells, who also has "Earthbound" set,up at The Film ...
... statement by James Firman, President and CEO, National Council ... statement on behalf of older Americans,yesterday. Following the dramatic ... the Democrats in the Senate and voted in favor ... Act, which,protects critical benefits for older people of limited ...
Cached Medicine News:Health News:Researchers: Program discourages HIV transmission in Russia 2Health News:RiderSaver(TM) EMF Seat Shield Reduces Motorcycle Cancer Concern 2Health News:Grand Opening of Xinyu Elegant's Vacheron Constantin Boutique 2Health News:Once Again Among the Nation's Finest: U-M Hospitals & Health Centers Rank 13th in the U.S. 2Health News:Once Again Among the Nation's Finest: U-M Hospitals & Health Centers Rank 13th in the U.S. 3Health News:Whitaker and Broome Get Wells 'Fat' at HBO 2Health News:NCOA Applauds Senate Passage of Medicare Bill 2
... Lyphochek Fertility Control ... monitor the clinically significant ... most frequently assayed during ... Elevated hCG and hCG-Beta ...
Liquichek Spinal Fluid Control is a liquid, bilevel product designed to monitor the performance of automated and manual procedures for the analysis of proteins and other critical analytes assayed in ...
The Acceava hCG Combo test provides superior performance for the diagnosis of pregnancy with a simple procedure that provides easy to read black on white results in 3 minutes for urine or 5 minutes f...
... Nucleic Sample Preparation Platform provides flexible, automated ... platform can prepare up to 96 patient ... and one half-hours, and performs onboard quantitation ... 30 minutes each. Based on Beckman ...
Medicine Products: